top of page


ImmunityBio begins European patient treatment with Anktiva plus BCG for bladder cancer
ImmunityBio has begun treating patients in Europe with Anktiva plus BCG for a defined form of BCG-unresponsive bladder cancer, marking an early commercial-access milestone following its existing European authorisation.

nuaxia
Nov 62 min read


FDA Approves AstraZeneca’s Imfinzi Plus BCG for High-Risk Bladder Cancer
The approval introduces the first immunotherapy combination for BCG-naïve high-risk non-muscle-invasive bladder cancer, marking a potential shift in the standard of care.

nuaxia
Jun 22 min read
bottom of page